Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SVRA Savara Inc

Post-Market Trading 03-31 18:36:44 EDT

2.77

-0.14

-4.81%

盘后2.89

+0.12+4.33%

17:59 EDT

High2.88	Low2.68	Vol1.62M
Open2.81	D1 Closing2.91	Amplitude6.87%
Mkt Cap478.19M	Tradable Cap282.54M	Total Shares172.63M
T/O4.48M	T/O Rate1.59%	Tradable Shares102.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"SVRA","market":"US","secType":"STK","nameCN":"Savara Inc","latestPrice":2.77,"timestamp":1743451200000,"preClose":2.91,"halted":0,"volume":1620484,"hourTrading":{"tag":"盘后","latestPrice":2.89,"preClose":2.77,"latestTime":"17:59 EDT","volume":145673,"amount":405027.22804719995,"timestamp":1743458358155},"delay":0,"floatShares":102000000,"shares":172633140,"eps":-0.483778,"marketStatus":"Post-Market Trading","change":-0.14,"latestTime":"03-31 18:36:44 EDT","open":2.81,"high":2.88,"low":2.68,"amount":4484691.7386776,"amplitude":0.068729,"askPrice":3.14,"askSize":100,"bidPrice":2.54,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.483778,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743465600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.91,"postHourTrading":{"tag":"盘后","latestPrice":2.89,"preClose":2.77,"latestTime":"17:59 EDT","volume":145673,"amount":405027.22804719995,"timestamp":1743458358155},"volumeRatio":1.740181,"impliedVol":0.4089,"impliedVolPercentile":0.2351},"requestUrl":"/m/hq/s/SVRA/wiki","defaultTab":"wiki","newsList":[{"id":"2523919864","title":"Savara Inc - Terminates Atm Agreement With Evercore Effective April 2, 2025 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2523919864","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523919864?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 18:11","pubTimestamp":1743415864,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC07Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2522522762","title":"Savara Price Target Maintained With a $6.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522522762","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522522762?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:10","pubTimestamp":1743160200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SVRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 28, 2025 07:10 ET (11:10 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA"],"gpt_icon":0},{"id":"2522376273","title":"Savara Q4 2024 GAAP EPS $(0.13) Misses $(0.11) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522376273","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522376273?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:18","pubTimestamp":1743074328,"startTime":"0","endTime":"0","summary":"Savara Q4 2024 GAAP EPS $(0.13) Misses $(0.11) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44511060/savara-q4-2024-gaap-eps-0-13-misses-0-11-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA"],"gpt_icon":0},{"id":"2522754603","title":"BRIEF-Savara Q4 Net Income USD -29.044 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522754603","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522754603?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:05","pubTimestamp":1743073545,"startTime":"0","endTime":"0","summary":"BRIEF-Savara Q4 Net Income USD -29.044 Million\n\n\nMar 27 (Reuters) - Savara Q4 income from operations USD -31.174 million vs. IBES estimate USD -24.8 million.\n\nQ4 operating expenses USD 31.174 million\nQ4 basic EPS USD -0.13 vs. IBES estimate USD -0.11","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLXA15EB3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2522461375","title":"Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522461375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522461375?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:05","pubTimestamp":1743073500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA1STTQT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2522375483","title":"Savara Q4 Net Income USD -29.044 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375483","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375483?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:05","pubTimestamp":1743073500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLXA15EB3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2522375457","title":"Savara Q4 Basic EPS USD -0.13 VS. Ibes Estimate USD -0.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375457","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375457?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:05","pubTimestamp":1743073500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLXA15EB3:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2522752813","title":"Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522752813","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522752813?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:05","pubTimestamp":1743073500,"startTime":"0","endTime":"0","summary":"-- Completed Submission of the Biologics License Application  to the U.S. Food and Drug Administration  for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis  --. -- Priority Review Was Requested, Commercial Launch Preparations Underway --. \"Completing submission of the BLA is an important milestone in potentially addressing the significant unmet need of people living with aPAP, a rare and debilitating lung disease,\" said Matt Pauls, Chair and Chief Executive Officer, Savara. \"MOLBREEVI has the potential to be the first and only approved therapy for aPAP in the U.S. and Europe and could redefine the standard of care for the disease. If granted Priority Review, we could have a PDUFA date by the end of the year and are preparing for a commercial launch in early 2026. Lastly, with approximately $196 million in cash, we are in a strong financial position and believe our cash runway extends through 2Q 2027, excluding our recent debt financing which adds additional low-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-reports-fourth-quarter-end-110500201.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IP","PIM","BK4136","LU2463526074.USD","BK4585","SVRA","LU1481599808.USD","BK4139","BK4588","LU1487256676.USD","LU1481600234.SGD"],"gpt_icon":0},{"id":"2522359103","title":"Savara Gets Up to $200 Million Loan From Hercules Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2522359103","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522359103?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 05:22","pubTimestamp":1743024147,"startTime":"0","endTime":"0","summary":"Savara  said Wednesday it entered into a loan and security agreement of up to $200 million with Hercules Capital .The debt financing strengthens Savara's balance sheet following its filing of a biologics license application with the US Food and Drug Administration for Molbreevi to treat autoimmune pulmonary alveolar proteinosis, a rare lung disease, the company said.If the FDA grants priority review, Molbreevi could be approved by the end of the year, Savara said, adding that it is also on track to file a marketing authorization application in Europe by year-end.Savara said $30 million was funded at the execution of the agreement and will be used to repay an existing $26.5 million debt facility. An additional $100 million will be available upon Molbreevi's FDA approval and other milestones.The final $70 million may be made available at Hercules Capital's discretion upon Savara's request, according to the company.Shares of Savara were up nearly 2% in after-hours trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-gets-200-million-loan-212227805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","HTGC","SVRA","BK4135"],"gpt_icon":0},{"id":"2522353018","title":"BRIEF-Savara Enters Into Non-Dilutive Debt Financing For Up To $200M With Hercules Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2522353018","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522353018?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:47","pubTimestamp":1743022024,"startTime":"0","endTime":"0","summary":"BRIEF-Savara Enters Into Non-Dilutive Debt Financing For Up To $200M With Hercules CapitalMarch 26 (Reuters) - Savara Inc SVRA.O:SAVARA ENTERS INTO NON-DILUTIVE DEBT FINANCING FOR UP TO $200M WITH HER","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q917T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139","HTGC","BK4135"],"gpt_icon":0},{"id":"2522835377","title":"Savara Files Biologics License Application to US FDA for Molbreevi to Treat Lung Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2522835377","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522835377?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:44","pubTimestamp":1743021886,"startTime":"0","endTime":"0","summary":"Savara  said late Wednesday it has completed submission of a biologics license application to the US Food and Drug Administration for Molbreevi to treat autoimmune pulmonary alveolar proteinosis, a rare lung disease.Savara requested priority review, which, if granted, will shorten the FDA's review to six months from the standard 10 months following the regulator's acceptance of the application, Chief Executive Matt Pauls said in a statement. The company remains on track with its commercial preparations to support a possible launch of the drug in early 2026, he added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2522585483","title":"Savara completes BLA submission to FDA for Molbreevi","url":"https://stock-news.laohu8.com/highlight/detail?id=2522585483","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522585483?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:11","pubTimestamp":1743019870,"startTime":"0","endTime":"0","summary":"Savara (SVRA) announced that it has completed submission of the BLA to the FDA for MOLBREEVI as a treatment for aPAP. “Submission of the BLA marks ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/savara-completes-bla-submission-to-fda-for-molbreevi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/savara-completes-bla-submission-to-fda-for-molbreevi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2522330496","title":"BRIEF-Savara Completes Submission Of The Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For MOLBREEVI As A Treatment For Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522330496","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522330496?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:07","pubTimestamp":1743019678,"startTime":"0","endTime":"0","summary":"BRIEF-Savara Completes Submission Of The Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For MOLBREEVI As A Treatment For Autoimmune Pulmonary Alveolar Proteinosis (","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA3YKFVL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2522998330","title":"Savara Completes Submission of the Biologics License Application (Bla) to the U.S. Food and Drug Administration (FDA) for Molbreevi* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (Apap)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522998330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522998330?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:05","pubTimestamp":1743019500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA3YKFVL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2522333010","title":"Savara Inc: Commercial Preparations Are on-Track to Support a Potential Launch in Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2522333010","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522333010?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:05","pubTimestamp":1743019500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA3YKFVL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2522301243","title":"Savara Inc - to Submit Molbreevi Maa in Europe by End of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522301243","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522301243?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:05","pubTimestamp":1743019500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA3YKFVL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2522353711","title":"Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522353711","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522353711?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:05","pubTimestamp":1743019500,"startTime":"0","endTime":"0","summary":"-- Priority Review Was Requested, Commercial Launch Preparations Underway --. LANGHORNE, Pa., March 26, 2025----Savara Inc.  , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has completed submission of the BLA to the FDA for MOLBREEVI as a treatment for aPAP.\"Submission of the BLA marks an important milestone for the Company and the aPAP community,\" said Matt Pauls, Chair and Chief Executive Officer, Savara. \"We believe this unprecedented body of data demonstrates MOLBREEVI improves pulmonary gas exchange and the clinical symptoms associated with this rare lung disease. As part of the submission, Priority Review was requested and, if granted, would shorten the FDA’s review to six months  following the Agency’s acceptance of the application. We look forward to continuing our dialogue with the FDA and extend our gratitude to the patients and physicians who participated in our clinical trials. Our commercial preparations are on-tra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-completes-submission-biologics-license-200500101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1487256676.USD","SVRA","MAA","IP","LU1481599808.USD","LU1481600234.SGD","BK4585","BK4588","PIM","LU2463526074.USD","BK4136","BK4139","BK4215"],"gpt_icon":0},{"id":"2521288795","title":"Savara Inc  expected to post a loss of 11 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2521288795","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521288795?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 20:01","pubTimestamp":1742558483,"startTime":"0","endTime":"0","summary":"Savara Inc  expected to post a loss of11cents a share - Earnings Preview Savara Inc SVRA.OQ SVRA.O is expected to show no change in quarterly revenue when it reports  results on March 24 (estimated) f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q40X0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA"],"gpt_icon":0},{"id":"2520520888","title":"Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520520888","media":"Business Wire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520520888?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 20:05","pubTimestamp":1742213100,"startTime":"0","endTime":"0","summary":"-- Company to Host Industry Theater on aPAP with Two World-Renowned Experts --. LANGHORNE, Pa., March 17, 2025----Savara Inc.  , a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society  International Conference taking place May 16-21, 2025, in San Francisco, CA. The Company will also host an Industry Theater titled \"Advances in Autoimmune Pulmonary Alveolar Proteinosis \" at the meeting.The abstracts will be published in a supplement of the American Journal of Respiratory and Critical Care Medicine on May 1, 2025. For more details about the ATS International Conference please visit their website.aPAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-present-data-phase-3-120500851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SVRA","ATS","BK4161","BK4117","BK4107","AFG","BK4139"],"gpt_icon":0},{"id":"2518244943","title":"Savara Inc  expected to post a loss of 11 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2518244943","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518244943?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 19:05","pubTimestamp":1741604737,"startTime":"0","endTime":"0","summary":"Savara Inc  expected to post a loss of11cents a share - Earnings Preview Savara Inc SVRA.OQ SVRA.O is expected to show no change in quarterly revenue when it reports  results on March 12 (estimated) f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL8N3PT0M1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.savarapharma.com;www.masttherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0319},{"period":"1month","weight":0.1781},{"period":"3month","weight":-0.0762},{"period":"6month","weight":-0.3137},{"period":"1year","weight":-0.4157},{"period":"ytd","weight":-0.0521}],"compareEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.0654},{"period":"3month","weight":-0.0661},{"period":"6month","weight":-0.0277},{"period":"1year","weight":0.0623},{"period":"ytd","weight":-0.0519}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.121255},{"month":2,"riseRate":0.25,"avgChangeRate":-0.051283},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.006625},{"month":4,"riseRate":0.583333,"avgChangeRate":0.025179},{"month":5,"riseRate":0.75,"avgChangeRate":0.049473},{"month":6,"riseRate":0.5,"avgChangeRate":-0.036588},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.037047},{"month":8,"riseRate":0.5,"avgChangeRate":-0.004589},{"month":9,"riseRate":0.5,"avgChangeRate":0.004673},{"month":10,"riseRate":0.083333,"avgChangeRate":-0.1617},{"month":11,"riseRate":0.5,"avgChangeRate":0.099362},{"month":12,"riseRate":0.583333,"avgChangeRate":0.241594}],"exchange":"NASDAQ","name":"Savara Inc","nameEN":"Savara Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Savara Inc(SVRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Savara Inc,SVRA,Savara Inc股票,Savara Inc股票老虎,Savara Inc股票老虎国际,Savara Inc行情,Savara Inc股票行情,Savara Inc股价,Savara Inc股市,Savara Inc股票价格,Savara Inc股票交易,Savara Inc股票购买,Savara Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Savara Inc(SVRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}